MESO Nasdaq update, page-816

It was a great post, thank you @otherperspective. The moderation was a bit tough in that the post was actually correcting serious misunderstandings and misdirections amongst followers of the other thread, issues that could cost less informed readers money. A number of posters there had claimed superiority of their favoured cells vs MSB's and OP answered that.

Anyway, so be it. The irony is that if that post had been lodged here it would have been read by many if not most of the "competitor's" followers because it is obvious that they spend time here. Nothing wrong with that.

My main takes from OP's post were that comparing mortality rates between a successful phase 1, 15 or 16 subject trial and a successful phase 3 is pointless when Ryoncil is considered curative of aGvHD in the majority of patients. There isn't anything better than that.

Also, that repeatedly claiming "better, faster, cheaper" for cells other than MSB is not only wrong, but more wrong by the day. There is increasing evidence that cell manufacture will not be a problem for MSB. Except perhaps that a possible worldwide, colossal demand could not be satisfied by any process at all.

The majority of MSB investors are very happy with their investment. Enough said.